Repligen completes BioLife Solutions acquisition for cell therapy push
Repligen Corporation has completed its acquisition of BioLife Solutions, folding the cell-processing tools supplier into its bioprocessing portfolio. BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with fractional shares settled in cash.
The Waltham, Massachusetts-listed company said the deal broadens its footprint in the cell and gene therapy market, adding BioLife's biopreservation media range to its existing filtration, chromatography, and process analytics businesses. BioLife's flagship CryoStor product is embedded in the workflows supporting 18 commercially approved cell-based therapies and a majority of US commercially sponsored cell therapy trials, a level of installed-base penetration that carries meaningful switching costs for customers.
Repligen chief executive Olivier Loeillot said the combined commercial team would be better placed to "support customers across critical stages of the cell therapy workflow," while giving BioLife access to Repligen's Asia Pacific distribution network. Loeillot described BioLife's consumables business as high-margin with attractive recurring revenue characteristics, a profile that should support Repligen's gross margin profile as the broader bioprocessing sector works through a post-pandemic destocking cycle.
Repligen said it will quantify the transaction's impact on its 2026 financial outlook during the forthcoming third-quarter earnings call. The company did not publish a standalone acquisition price in today's release; the implied value will depend on Repligen's share price at close.
Market context
The deal arrives at a pivotal moment for cell and gene therapy bioprocessing. Contract development and manufacturing organisations and emerging biotech sponsors have been scaling up commercial-stage manufacturing capacity for approved CAR-T and other cell therapies, driving sustained demand for cold-chain consumables, closed-system processing equipment and cryopreservation media. BioLife's biopreservation products sit at a particularly defensible point in that workflow: swapping out media formulations validated during clinical development is operationally costly, giving embedded suppliers pricing durability that commodity equipment vendors lack.
Repligen is not alone in pursuing bolt-on acquisitions to build out cell therapy bioprocessing coverage. Several larger life sciences tools companies have moved to consolidate specialised cell-therapy suppliers in recent years, compressing the universe of independent mid-tier targets. For Repligen, which has historically focused on upstream bioreactor and filtration applications for traditional biologics manufacturing, BioLife represents a deliberate downstream extension into cell-therapy-specific consumables.
Regulatory and competitive read-across
The FDA has continued to approve cell-based therapies at a steady pace across oncology and rare-disease indications, and the pipeline of late-stage candidates points to further commercial launches over the next two to three years. Each new approval typically converts an existing clinical-stage supply relationship into a long-term commercial one, compounding the recurring revenue dynamics that Loeillot highlighted. Regulatory pressure on manufacturing quality and cold-chain integrity in cell therapy has also increased scrutiny of biopreservation steps, a tailwind for suppliers whose media have already passed the validation bar at multiple commercial manufacturers.
Perella Weinberg Partners and Goldman Sachs advised Repligen; Centerview Partners advised BioLife.